Clinical Trial Update: Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

View source ↗

Summary

A clinical trial update assessing the minimal important difference for the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) in adult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency | Status: COMPLETED